Drugs / Renamezin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02681991 | Jan → Sep 2016 | chronic renal failure syndrome | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02681952 Comparator | Dec 2015 → Dec 2016 | chronic renal failure syndrome | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Renamezin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02681991 ↗ |
| Route | Oral | “Renamezin capsule 2g, tid, PO” NCT02681991 ↗ |